Show simple item record

Development of a contemporary globally diverse HIV viral panel by the EQAPOL program

dc.contributor.author Brinkley, Christie
dc.contributor.author Busch, Michael P
dc.contributor.author Chen, Y
dc.contributor.author Demarco, C Todd
dc.contributor.author Denny, Thomas Norton
dc.contributor.author Gao, Feng
dc.contributor.author Hora, Bhavna
dc.contributor.author Keating, S
dc.contributor.author Keinonen, Sarah
dc.contributor.author Sanchez, Ana M
dc.contributor.author Schito, M
dc.contributor.author Stone, M
dc.contributor.author Tobler, L
dc.date.accessioned 2017-06-01T20:11:05Z
dc.date.available 2017-06-01T20:11:05Z
dc.date.issued 2014-01-01
dc.identifier.issn 0022-1759
dc.identifier.uri https://hdl.handle.net/10161/14716
dc.description.abstract The significant diversity among HIV-1 variants poses serious challenges for vaccine development and for developing sensitive assays for screening, surveillance, diagnosis, and clinical management. Recognizing a need to develop a panel of HIV representing the current genetic and geographic diversity NIH/NIAID contracted the External Quality Assurance Program Oversight Laboratory (EQAPOL) to isolate, characterize and establish panels of HIV-1 strains representing global diverse subtypes and circulating recombinant forms (CRFs), and to make them available to the research community. HIV-positive plasma specimens and previously established isolates were collected through a variety of collaborations with a preference for samples from acutely/recently infected persons. Source specimens were cultured to high-titer/high-volume using well-characterized cryopreserved PBMCs from National y donors. Panel samples were stored as neat culture supernatant or diluted into defibrinated plasma. Characterization for the final expanded virus stocks included viral load, p24 antigen, infectivity (TCID), sterility, coreceptor usage, and near full-length genome sequencing. Viruses are made available to approved, interested laboratories using an online ordering application. The current EQAPOL Viral Diversity panel includes 100 viral specimens representing 6 subtypes (A, B, C, D, F, and G), 2 sub-subtypes (F1 and F2), 7 CRFs (01, 02, 04, 14, 22, 24, and 47), 19 URFs and 3 group O viruses from 22 countries. The EQAPOL Viral Diversity panel is an invaluable collection of well-characterized reagents that are available to the scientific community, including researchers, epidemiologists, and commercial manufacturers of diagnostics and pharmaceuticals to support HIV research, as well as diagnostic and vaccine development. © 2014 Elsevier B.V.
dc.relation.ispartof Journal of Immunological Methods
dc.relation.isversionof 10.1016/j.jim.2014.01.004
dc.title Development of a contemporary globally diverse HIV viral panel by the EQAPOL program
dc.type Journal article
pubs.begin-page 117
pubs.end-page 130
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Human Vaccine Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Duke Human Vaccine Institute
pubs.organisational-group Medicine, Infectious Diseases
pubs.organisational-group School of Medicine
pubs.publication-status Published
pubs.volume 409
dc.identifier.eissn 1872-7905


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record